Skip to main content

High prevalence of CTX-M-associated multidrug resistance and diagnostic accuracy of NG-Test CTX-M Multi among ESBL-producing Escherichia coli in Vietnam

In brief

CTX-M appeared in 69% of ESBL E. coli at one Vietnam hospital

Among 180 extended-spectrum beta-lactamase-producing E. coli isolates, 124 carried CTX-M; nearly 7 in 10 of those showed resistance across at least six antimicrobial classes. A rapid CTX-M test identified positive isolates with 92% sensitivity and 95% specificity, but it was assessed in only 76 isolates, so larger studies are needed before its performance is certain elsewhere.

Journal
Microbiology spectrum (Q1)
Published
20 November 2026
Study design
Cross-sectional study
Evidence level
Level 3, Low (CEBM 3b)
Authors
Thi Loan Le, Si-Tuan Nguyen, Van Chuong Le, Thuy Loan Chi Nguyen, Thi Hang Nguyen, Friend Maviza
PMID
43062049
DOI
10.1128/spectrum.01330-26

Why clinicians should know about it

  • Picked for Microbiology (medical) (paper of the day, 21 November 2026): Evaluates rapid CTX-M assay accuracy and ESBL resistance epidemiology

Abstract

CTX-M enzymes are the predominant extended-spectrum β-lactamases (ESBLs) worldwide, yet local epidemiology in Vietnam remains incompletely characterized. This study investigated CTX-M prevalence among ESBL-producing Escherichia coli from inpatients at a tertiary-care hospital in Ho Chi Minh City and evaluated the diagnostic performance of the NG-Test CTX-M Multi assay. A prospective cross-sectional study was conducted at FV Hospital from January 2024 to April 2025. ESBL-producing E. coli flagged by the VITEK 2 Advanced Expert System (AES) were tested with NG-Test CTX-M Multi (NG Biotech, France). Antimicrobial susceptibility testing followed CLSI M100 guidelines (2024). Diagnostic accuracy was assessed against multiplex real-time PCR (Allplex Entero-DR Assay) in a blinded evaluation of 76 isolates. Of the 461 E. coli isolates, 180 (39.0%) were ESBL producers; CTX-M was detected in 124 (68.9%). CTX-M-positive isolates showed significantly higher resistance to cefotaxime (98.4% vs 28.5%), cefepime (78.2% vs 10.7%), gentamicin (37.9% vs 12.7%), and ciprofloxacin (74.8% vs 73.2%); all P < 0.05. Carbapenems and amikacin retained high susceptibility (>95%) in both groups. CTX-M-positive isolates exhibited broader resistance profiles (≥6 antimicrobial classes: 68.9% vs 27.8%). AmpC flagging was more frequent in CTX-M-negative isolates (69.6% vs 28.2%; P < 0.001). NG-Test CTX-M Multi demonstrated 92.1% sensitivity (95% confidence interval [CI], 79.2-97.3), 94.7% specificity (95% CI, 82.7-98.5), PPV 94.6%, and NPV 92.3%. CTX-M was the dominant ESBL mechanism and was associated with broader multidrug resistance. NG-Test CTX-M Multi showed high diagnostic accuracy, supporting its role as a rapid screening tool; however, larger validation studies are warranted.IMPORTANCEInfections caused by Escherichia coli producing extended-spectrum beta-lactamases (ESBLs) pose a significant challenge for clinical management because they limit the effectiveness of commonly used antibiotics. CTX-M enzymes are now well established as the dominant ESBL determinants worldwide; however, their local prevalence and associated antimicrobial resistance patterns continue to vary across healthcare settings. In this study, we investigated the prevalence of CTX-M-producing E. coli and their resistance profiles in a tertiary care hospital in Vietnam. Our findings demonstrate a substantial burden of CTX-M-associated multidrug resistance affecting both hospital- and community-associated infections. In addition, the evaluation of a rapid lateral flow immunoassay for CTX-M detection highlights its potential role as a practical screening tool to support timely antimicrobial decision-making and infection control efforts. Together, these results provide clinically relevant data to support antimicrobial stewardship and optimize the management of infections caused by resistant E. coli.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.